{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:40:39Z","timestamp":1794354039260,"version":"4.9.0"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"4","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1801525N"],"award-info":[{"award-number":["1801525N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["2024-185_C2728"],"award-info":[{"award-number":["2024-185_C2728"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1150526N"],"award-info":[{"award-number":["1150526N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G026325N"],"award-info":[{"award-number":["G026325N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G026225N"],"award-info":[{"award-number":["G026225N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The ccrcc1\u20134 transcriptomic subtypes were previously identified in fresh-frozen clear-cell renal cell carcinoma (ccRCC) samples and have proven their prognostic value after nephrectomy\/metastasectomy and predictive value for first-line vascular endothelial growth factor receptor\u2013tyrosine kinase inhibitors (VEGFR-TKI). We aimed to create a consensus molecular classification approach called Clearseq1\u20134 on formalin-fixed, paraffin-embedded (FFPE) tissues and to evaluate its prognostic and predictive value across the RCC treatment landscape. RNA sequencing of tumoral FFPE tissue was performed. A classifier called Clearseq was designed to determine ccrcc1\u20134 subtypes. Subtypes were correlated with outcomes after surgical and systemic therapies. External validation and characterization at the single-cell transcriptomic level were pursued. A total of 668 tumoral samples (337 primary tumors and 331 metastases) from 364 patients were assigned to ccrcc1, ccrcc2, ccrcc3, and ccrcc4 tumors. The angiogenic ccrcc2 subtype had a favorable prognosis after nephrectomy in a localized setting, after cytoreductive nephrectomy, and upon metastasectomy with curative intent and was correlated with improved outcomes on first-line VEGFR-TKIs. Ccrcc4 tumors were enriched for sarcomatoid features and had the largest treatment benefit from immune checkpoint blockade (ICB) treatment in any line, resulting in overall survival outcomes comparable with those of less aggressive subtypes. These findings were corroborated in a post-nephrectomy cohort and external cohorts of metastatic patients treated with ICB and\/or angiogenesis inhibitors. We created a consensus molecular classification approach, called Clearseq1\u20134, in order to predict the ccrcc1\u20134 molecular subtype on FFPE tissues and confirmed its performance with respect to previous biomarker findings for both surgical and systemic treatment approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Clear-cell kidney cancers display a more indolent or aggressive clinical behavior after surgery and different sensitivities to currently available medical therapies: immune therapy or angiogenesis inhibitors. We developed an easy-to-use molecular classification that divides these tumors into four subgroups predicting outcomes after surgery or upon medical therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0548","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:27:47Z","timestamp":1776713267000},"page":"884-897","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic and Predictive Value of the Clearseq1\u20134 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7479-4793","authenticated-orcid":false,"given":"Lisa","family":"Kinget","sequence":"first","affiliation":[{"name":"1Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium."},{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 2 Laboratory of Experimental Oncology (LEO), Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4710-7670","authenticated-orcid":false,"given":"Edward Scott","family":"McTaggart","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 3 Laboratory of Computational Oncology, Department of Oncology, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5986-2221","authenticated-orcid":false,"given":"Octavie","family":"Demeulenaere","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 4 Laboratory of Cell Stress & Immunity (CSI), Department of Cellular and Molecular Medicine, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-5536","authenticated-orcid":false,"given":"Eduard","family":"Roussel","sequence":"additional","affiliation":[{"name":"5Department of Urology, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-6680","authenticated-orcid":false,"given":"Bram","family":"Boeckx","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 6 Laboratory of Translational Genetics, Department of Human Genetics, , Leuven, Belgium."},{"name":"7VIB Center for Cancer Biology, VIB, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-0334","authenticated-orcid":false,"given":"Jessica","family":"Zucman-Rossi","sequence":"additional","affiliation":[{"name":"8Inserm, UMR-1138, G\u00e9nomique fonctionnelle des tumeurs solides, Institut de recherche des Cordeliers, Universit\u00e9 Paris Descartes, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3999-0062","authenticated-orcid":false,"given":"Gabrielle","family":"Couchy","sequence":"additional","affiliation":[{"name":"8Inserm, UMR-1138, G\u00e9nomique fonctionnelle des tumeurs solides, Institut de recherche des Cordeliers, Universit\u00e9 Paris Descartes, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-3116","authenticated-orcid":false,"given":"Henri","family":"Vandermeulen","sequence":"additional","affiliation":[{"name":"9Department of Radiology, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-7573","authenticated-orcid":false,"given":"Liesbeth","family":"De Wever","sequence":"additional","affiliation":[{"name":"9Department of Radiology, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0882-2944","authenticated-orcid":false,"given":"Marcella","family":"Baldewijns","sequence":"additional","affiliation":[{"name":"10Department of Pathology, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9726-144X","authenticated-orcid":false,"given":"Agnieszka","family":"Wozniak","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 2 Laboratory of Experimental Oncology (LEO), Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3195-9890","authenticated-orcid":false,"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[{"name":"5Department of Urology, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3429-302X","authenticated-orcid":false,"given":"Diether","family":"Lambrechts","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 6 Laboratory of Translational Genetics, Department of Human Genetics, , Leuven, Belgium."},{"name":"7VIB Center for Cancer Biology, VIB, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-6374","authenticated-orcid":false,"given":"Stefan","family":"Naulaerts","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 3 Laboratory of Computational Oncology, Department of Oncology, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-9922","authenticated-orcid":false,"given":"Abhishek D.","family":"Garg","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 4 Laboratory of Cell Stress & Immunity (CSI), Department of Cellular and Molecular Medicine, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9024-863X","authenticated-orcid":false,"given":"Annelies","family":"Verbiest","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01hwamj44","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Antwerp 11 Department of Medical Oncology, Multidisciplinary Oncological Center Antwerp (MOCA), , Edegem, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6763-6586","authenticated-orcid":false,"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[{"name":"5Department of Urology, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7427-9102","authenticated-orcid":false,"given":"Benoit","family":"Beuselinck","sequence":"additional","affiliation":[{"name":"1Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium."},{"id":[{"id":"https:\/\/ror.org\/05f950310","id-type":"ROR","asserted-by":"publisher"}],"name":"KU Leuven 2 Laboratory of Experimental Oncology (LEO), Department of Oncology, Leuven Cancer Institute, , Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"2026042015274271400_bib1","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2026042015274271400_bib2","doi-asserted-by":"crossref","first-page":"e430734","DOI":"10.1200\/EDBK_430734","article-title":"Update on biomarkers in renal cell carcinoma","volume":"44","author":"Saliby","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026042015274271400_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1947601909359929","article-title":"Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns","volume":"1","author":"Brannon","year":"2010","journal-title":"Genes Cancer"},{"key":"2026042015274271400_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.eururo.2014.02.035","article-title":"ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma","volume":"66","author":"Brooks","year":"2014","journal-title":"Eur Urol"},{"key":"2026042015274271400_bib5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1158\/1078-0432.CCR-14-1128","article-title":"Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting","volume":"21","author":"Beuselinck","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026042015274271400_bib6","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/j.clgc.2021.07.005","article-title":"Molecular subtypes and gene expression signatures as prognostic features in fully resected clear cell renal cell carcinoma: a tailored approach to adjuvant trials","volume":"19","author":"Roussel","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"2026042015274271400_bib7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.eururo.2018.01.042","article-title":"Molecular subtypes of clear-cell renal cell carcinoma are prognostic for outcome after complete metastasectomy","volume":"74","author":"Verbiest","year":"2018","journal-title":"Eur Urol"},{"key":"2026042015274271400_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"2026042015274271400_bib9","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2159-8290.CD-18-0957","article-title":"Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial","volume":"9","author":"Hakimi","year":"2019","journal-title":"Cancer Discov"},{"key":"2026042015274271400_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"2026042015274271400_bib11","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ccell.2024.03.002","article-title":"Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes","volume":"42","author":"Saliby","year":"2024","journal-title":"Cancer Cell"},{"key":"2026042015274271400_bib12","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1158\/1078-0432.CCR-22-0923","article-title":"Transcriptomic correlates of tumor cell PD-L1 expression and response to nivolumab monotherapy in metastatic clear cell renal cell carcinoma","volume":"28","author":"Denize","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026042015274271400_bib13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(22)00128-0","article-title":"Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial","volume":"23","author":"Vano","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"2026042015274271400_bib14","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/oncolo\/oyad216.023","article-title":"OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)","volume":"28","author":"Beckermann","year":"2023","journal-title":"Oncologist"},{"key":"2026042015274271400_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.euros.2022.04.004","article-title":"Molecular heterogeneity between paired primary and metastatic lesions from clear cell renal cell carcinoma","volume":"40","author":"Roussel","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"2026042015274271400_bib16","doi-asserted-by":"crossref","first-page":"lqaa078","DOI":"10.1093\/nargab\/lqaa078","article-title":"ComBat-seq: batch effect adjustment for RNA-seq count data","volume":"2","author":"Zhang","year":"2020","journal-title":"NAR Genom Bioinform"},{"key":"2026042015274271400_bib17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bjc.2015.352","article-title":"RANK\/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs","volume":"113","author":"Beuselinck","year":"2015","journal-title":"Br J Cancer"},{"key":"2026042015274271400_bib18","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"key":"2026042015274271400_bib19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"2026042015274271400_bib20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"2026042015274271400_bib21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nbt.3772","article-title":"Toil enables reproducible, open source, big biomedical data analyses","volume":"35","author":"Vivian","year":"2017","journal-title":"Nat Biotechnol"},{"key":"2026042015274271400_bib22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2026042015274271400_bib23","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.12688\/f1000research.25141.1","article-title":"CRI iAtlas: an interactive portal for immuno-oncology research","volume":"9","author":"Eddy","year":"2020","journal-title":"F1000Res"},{"key":"2026042015274271400_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"key":"2026042015274271400_bib25","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41591-024-02978-9","article-title":"A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma","volume":"30","author":"Kinget","year":"2024","journal-title":"Nat Med"},{"key":"2026042015274271400_bib26","doi-asserted-by":"crossref","first-page":"101377","DOI":"10.1016\/j.xcrm.2023.101377","article-title":"Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells","volume":"5","author":"Sprooten","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026042015274271400_bib27","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1016\/j.clgc.2017.10.017","article-title":"Molecular subtypes of clear cell renal cell carcinoma are associated with outcome during pazopanib therapy in the metastatic setting","volume":"16","author":"Verbiest","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"2026042015274271400_bib28","doi-asserted-by":"crossref","first-page":"eadm8660","DOI":"10.1126\/sciadv.adm8660","article-title":"Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy","volume":"10","author":"Vanmeerbeek","year":"2024","journal-title":"Sci Adv"},{"key":"2026042015274271400_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41421-023-00605-4","article-title":"Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer","volume":"9","author":"Borr\u00e0s","year":"2023","journal-title":"Cell Discov"},{"key":"2026042015274271400_bib30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1080\/0284186X.2021.1962971","article-title":"Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications","volume":"60","author":"Roussel","year":"2021","journal-title":"Acta Oncol"},{"key":"2026042015274271400_bib31","doi-asserted-by":"crossref","first-page":"e134564","DOI":"10.1172\/jci.insight.134564","article-title":"Pancreatic tropism of metastatic renal cell carcinoma","volume":"5","author":"Singla","year":"2020","journal-title":"JCI Insight"},{"key":"2026042015274271400_bib32","doi-asserted-by":"crossref","first-page":"e176230","DOI":"10.1172\/JCI176230","article-title":"Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma","volume":"134","author":"Gulati","year":"2024","journal-title":"J Clin Invest"},{"key":"2026042015274271400_bib33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2012.09.037","article-title":"Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma","volume":"63","author":"Tosco","year":"2013","journal-title":"Eur Urol"},{"key":"2026042015274271400_bib34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/0284186X.2017.1388927","article-title":"Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma","volume":"57","author":"Beuselinck","year":"2018","journal-title":"Acta Oncol"},{"key":"2026042015274271400_bib35","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41577-025-01161-6","article-title":"The diversity of CD8+ T cell dysfunction in cancer and viral infection","volume":"25","author":"Galluzzi","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"2026042015274271400_bib36","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"2026042015274271400_bib37","doi-asserted-by":"crossref","first-page":"eadd1016","DOI":"10.1126\/scitranslmed.add1016","article-title":"Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer","volume":"15","author":"Naulaerts","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026042015274271400_bib38","doi-asserted-by":"crossref","first-page":"e001506","DOI":"10.1136\/jitc-2020-001506","article-title":"Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC","volume":"9","author":"Ross-Macdonald","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026042015274271400_bib39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.annonc.2024.12.003","article-title":"Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma","volume":"36","author":"Motzer","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/884\/3775504\/crc-25-0548.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/884\/3775504\/crc-25-0548.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:27:53Z","timestamp":1776713273000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/4\/884\/783999\/Prognostic-and-Predictive-Value-of-the-Clearseq1-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0548","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32704892","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704829","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704859","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704847","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704835","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704823","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704889","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704877","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704865","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704853","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704841","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704883","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704871","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704895","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704838","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704826","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704868","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704856","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704844","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704832","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704886","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704874","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704862","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704850","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32704880","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8542091","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}